

GlobalSurg 3

Quality and outcomes in global cancer surgery:
a prospective, international cohort study



UNIVERSITY OF
BIRMINGHAM




THE UNIVERSITY
of EDINBURGH



SuRG
Surgical Research
Gateway Foundation

GlobalSurg Collaborative



 5000
Collaborators

 106
Countries

- ✓ Any hospital in the world performing acute general surgery can participate
- ✓ Individuals can participate as local collaborators or regional/country leads


GlobalSurg 2

- Explored the global burden of surgical site infection (SSI) after gastrointestinal surgery
- 12 539 patients
- 343 hospitals
- 66 countries




GlobalSurg 2

Wound infection more common in low-income countries



Drug-resistant bugs may be more common in low-income countries



Countries: 66 | Hospitals: 343
Collaborators: 1815 | Patients: 12 539

GlobalSurg 2: Massive global impact

Surgical site infection after gastrointestinal surgery in high-income, middle-income, and low-income countries: a prospective, international, multicentre cohort study

Overview of attention for article published in Lancet Infectious Diseases, February 2018



GlobalSurg author-collaborators



Your name here

[Lancet Infect Dis](#). 2018 Feb 13. pii: S1473-3099(18)30101-4. doi: 10.1016/S1473-3099(18)30101-4. [Epub ahead of print]

Surgical site infection after gastrointestinal surgery in high-income, middle-income, and low-income countries: a prospective, international, multicentre cohort study.

[GlobalSurg Collaborative](#).

Collaborators (1816)

[Bhangu A](#), [Ademuyiwa AO](#), [Aguilera ML](#), [Alexander P](#), [Al-Saqqa SW](#), [Borda-Luque G](#), [Costas-Chavarri A](#), [Drake TM](#), [Ntirenganya F](#), [Fitzgerald JE](#), [Fergusson SJ](#), [Glasbey J](#), [Ingabire JA](#), [Ismail L](#), [Salem HK](#), [Kojo ATT](#), [Lapitan MC](#), [Lilford R](#), [Mihaljevic AL](#), [Morton D](#), [Mutabazi AZ](#), [Nepogodiev D](#), [Adisa AO](#), [Ots R](#), [Pata F](#), [Pinkney T](#), [Poškus T](#), [Qureshi AU](#), [Ramos-De la Medina A](#), [Rayne S](#), [Shaw CA](#), [Shu S](#), [Spence R](#), [Smart N](#), [Tabiri S](#), [Harrison EM](#), [Khatri C](#), [Mohan M](#), [Jaffry Z](#), [Altamini A](#), [Kirby A](#), [Søreide K](#), [Recinos G](#), [Cornick J](#), [Modolo MM](#), [Iyer D](#), [King S](#), [Arthur T](#), [Nahar SN](#), [Waterman A](#), [Walsh M](#), [Aqarwal A](#), [Zani A](#), [Firdouse M](#), [Rouse T](#), [Liu Q](#), [Correa JC](#), [Talving P](#), [Worku M](#), [Arnaud A](#), [Kalles V](#), [Kumar B](#), [Kumar S](#), [Amandito R](#), [Quek R](#), [Ansaloni L](#), [Altibi A](#), [Venskutonis D](#), [Zilinskas J](#), [Poskus T](#), [Whitaker J](#), [Msosa V](#), [Tew YY](#), [Farrugia A](#), [Borg E](#), [Bentounsi Z](#), [Gala T](#), [Al-Slaibi I](#), [Tahboub H](#), [Alser OH](#), [Romani D](#), [Shu S](#), [Major P](#), [Mironescu A](#), [Bratu M](#), [Kourdouli A](#), [Ndajiwo A](#), [Altwijri A](#), [Alsaggaf MU](#), [Gudal A](#), [Jubran AF](#), [Seisay S](#), [Lieske B](#), [Ortega I](#), [Jeyakumar J](#), [Senanayake KJ](#), [Abdulbagi O](#), [Cengiz Y](#), [Raptis D](#), [Altinel Y](#), [Kong C](#), [Teasdale E](#), [Irwin G](#), [Stoddart M](#), [Kabariti R](#), [Suresh S](#), [Gash K](#), [Narayanan R](#), [Maimbo M](#), [Grizhja B](#), [Ymeri S](#), [Galiqi G](#), [Klappenbach R](#), [Antezana D](#), [Mendoza Beleño AE](#), [Costa C](#), [Sanchez B](#), [Aviles S](#), [Fermani CG](#), [Balmaceda R](#), [Villalobos S](#), [Carmona JM](#), [Hamill D](#), [Deutschmann P](#), [Sandler S](#), [Cox D](#), [Nataraja R](#), [Sharpin C](#), [Ljuhar D](#), [Gray D](#), [Haines M](#), [Iyer D](#), [Niranjan N](#), [D'Amours S](#), [Ashtari M](#), [Franco H](#), [Rahman Mitul A](#), [Karim S](#), [Aman NF](#), [Estee MM](#), [Salma U](#), [Razzaque J](#), [Hamid Kanta T](#), [Tori SA](#), [Alamin S](#), [Roy S](#), [Al Amin S](#), [Karim R](#), [Haque M](#), [Faruq A](#), [Iftekhar F](#), [O'Shea M](#), [Padmore G](#), [Jonnalagadda R](#), [Litvin A](#), [Filatau A](#), [Paulouski D](#), [Shubianok M](#), [Shachykava T](#), [Khokha D](#), [Khokha V](#), [Djivoh F](#), [Dossou F](#), [Seto DM](#), [Gbessi DG](#), [Noukpozoukoun B](#), [Imorou Souaibou Y](#), [Keke KR](#), [Hodonou F](#), [Ahounou EYS](#), [Alihonou T](#), [Dénakpo M](#), [Ahlonso G](#), [Ginbo Bedada A](#), [Nsengiyumva C](#), [Kwizera S](#), [Barendegere V](#), [Choi P](#), [Stock S](#), [Jamal L](#), [Azzie G](#), [Kushwaha S](#), [Chen TL](#), [Yip C](#), [Montes I](#), [Zapata F](#), [Sierra S](#), [Villegas Lanau MI](#), [Mendoza Arango MC](#), [Mendoza Restrepo I](#), [Restrepo Giraldo RS](#), [Domini E](#), [Karlo R](#), [Mihanovic J](#), [Youssef M](#), [Elfeki H](#), [Thabet W](#), [Sanad A](#), [Tawfik G](#), [Zaki A](#), [Abdel-Hameed N](#), [Mostafa M](#), [Omar MFW](#), [Ghanem A](#), [Abdallah E](#), [Denewer A](#), [Emara E](#), [Rashad E](#), [Sakr A](#), [Elashry R](#), [Emile S](#), [Khafagy T](#), [Elhamouly S](#), [Elfaragy A](#), [Mamdouh Mohamed A](#), [Saied Nagy G](#), [Esam A](#), [Elwy E](#), [Hammad A](#), [Khallaf S](#), [Ibrahim E](#), [Said Badr A](#), [Moustafa A](#), [Eldosouky Mohammed A](#), [Elgheriany M](#), [Abdelmageed E](#), [Al Raouf EA](#), [Samir Elbanby E](#), [Elmasry M](#), [Morsy Farahat M](#), [Yahya Mansor E](#), [Magdy Hegazy E](#), [Gamal E](#), [Gamal H](#), [Kandil H](#), [Maher Abdelrouf D](#), [Moaty M](#), [Gamal D](#), [El-Sagheer N](#), [Salah M](#), [Magdy S](#), [Salah A](#), [Essam A](#), [Ali A](#), [Badawy M](#), [Ahmed S](#), [Mohamed M](#), [Assal A](#), [Sleem M](#), [Ebidy M](#), [Abd-Elrazek A](#), [Zahrán D](#), [Adam N](#), [Nazir M](#), [Hassanein AB](#), [Ismail A](#), [Elsawy A](#), [Mamdouh R](#), [Mabrouk](#)




GlobalSurg 3: Cancer surgery



GlobalSurg 3:
Quality and outcomes in global
cancer surgery: a prospective,
international cohort study


- Major priority identified in the GlobalSurg prioritisation workshop

Incidence of cancer increasing everywhere



Assuming no change in underlying incidence

Death from cancer increasing in low & middle income countries



Relative Changes in Age-Standardized Cancer Mortality Rates in Both Sexes for All Cancers in 195 Countries or Territories From 2005 to 2015
GBD, JAMA Onc, April 2017

GlobalSurg 3: Aims

- Determine variation in quality of cancer surgery worldwide
- Breast, gastric & colon cancer
- Quality measures include
 - Infrastructure
 - Care processes
 - Outcomes
- Primary outcome measure
 - 30-day mortality/complication rates

GlobalSurg 3: Where & when?

- Any hospital, any where
 - performing surgery for breast/gastric/colon cancer
- Data collection
 - 4-week periods between April 1st & October 31st 2018
- Mini-teams of 3 individuals
 - medical students, doctors, nurses and researchers
 - Multiple teams across different periods encouraged
 - Avoid different teams for different cancers if possible



GlobalSurg 3: What do I do?

1. Subscribe to mailing list
2. Register your team to take part
 1. you will need an ORCID ID
3. Read the Study Protocol
4. Obtain the necessary local approvals
5. Complete the GlobalSurg 3 training module
6. Collect and enter your data

All at globalsurg.org/g3



GlobalSurg 3: Important

- Make sure you have approval before starting data collection
- National lead can advise you on what approvals you may need
- Considered an audit in the UK
 - still need Caldicott Guardian approval

Need more help?

- First point of contact
 - Hospital lead if you have one
- Second point of contact
 - National lead
 - Directly via globalsurg.org/contact/
- Third point of contact
 - enquiry@globalsurg.org
 - The inbox is very busy, so please only email if necessary



You can join the GlobalSurg Team!

